Loading...

ICU SEASTAR MEDICAL HOLDING CORP US FDA Inspections 8-K Filing

SSTR

C

SEASTAR MEDICAL HOLDING CORP

(ICU)

2025 8-K

Management Change

Financial Update

Salary Increases

Trial Continuation Approved

Management Changes

Filing Correction

Financial Results Update

Failure to Meet Standards

Notification of Listing Def...

Equity Offerings

Equity Offerings

Equity Offerings

Equity Offerings

Compensatory Arrangements o...

Financial Statements

Equity Offerings

Stockholder Approvals

Financial Results

Special Meeting Update

Nasdaq Listing Update

Securities Offering

Nasdaq Reprimand

Corporate Update

Nasdaq Delisting Notice

Stockholder Approvals

Financial Results

Contract Termination

Financial Results

Registered Direct Offering ...

Delisting Notice

Warrant Redemption Agreement

Redemption and Conversion o...

Management Changes

Reverse Stock Split

Submission of Matters to a ...

Results of Operations and F...

Bylaw Amendment

Financial Results Announcement

Restatement of Financial St...

Investor Conferences

FDA Approval for Selective ...

Termination of Agreement

Securities Purchase Agreement

Investment and Warrants Issued

Appointment of CFO

Delisting Notice

Delisting Notice

Additional Notes and Warran...

Appointment of New Independ...

Investment Completion

Financial Condition and Res...

FDA Approval for Pediatric ...

FDA Communication on HDE Ap...

Investment Completion

Amendment to Certificate of...

Special Meeting Approval

Financial Condition and Res...

Entry into a Material Defin...

Changes in Accounting Firm

Delisting Notice

Agreement with Vellar Oppor...

Financial Results Announcement

FDA Communications

Financial Results Announcement

Entry into Securities Purch...

Conference Call Announcement

FDA Approval for IDE Applic...

FDA IDE Application

External Links:

On September 24, 2025, SeaStar Medical announced that the Data Safety Monitoring Review Board recommended continuing the NEUTRALIZE-AKI trial and increasing patient enrollment to 339. The trial involves a device therapy for acute kidney injury with no reported safety issues.

AI Assistant

SEASTAR MEDICAL HOLDING CORP

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.